Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic s… Read more
Steminent Biotherapeutics Inc. (7729) - Net Assets
Latest net assets as of June 2025: NT$279.82 Million TWD
Based on the latest financial reports, Steminent Biotherapeutics Inc. (7729) has net assets worth NT$279.82 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$377.35 Million) and total liabilities (NT$97.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$279.82 Million |
| % of Total Assets | 74.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 109.39 |
Steminent Biotherapeutics Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Steminent Biotherapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Steminent Biotherapeutics Inc. (2020–2024)
The table below shows the annual net assets of Steminent Biotherapeutics Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$354.70 Million | -28.05% |
| 2023-12-31 | NT$492.99 Million | +201.45% |
| 2022-12-31 | NT$163.54 Million | -33.05% |
| 2021-12-31 | NT$244.27 Million | +1981.17% |
| 2020-12-31 | NT$-12.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Steminent Biotherapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 49765200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$560.45 Million | 158.01% |
| Other Components | NT$608.52 Million | 171.56% |
| Total Equity | NT$354.70 Million | 100.00% |
Steminent Biotherapeutics Inc. Competitors by Market Cap
The table below lists competitors of Steminent Biotherapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EP3
STU:EP3
|
$23.97K |
|
Irsa Wnt
BA:IRS2W
|
$23.99K |
|
FLRY3F
SA:FLRY3F
|
$24.01K |
|
Scherzer & Co. AG
F:PZS
|
$24.01K |
|
EDINBURGH WORLDW. LS-01
F:2TI
|
$23.95K |
|
216400
KO:216400
|
$23.94K |
|
Prospect Capital Corporation
NASDAQ:PSEC
|
$23.90K |
|
SCG Construction JSC
VN:SCG
|
$23.90K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Steminent Biotherapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 492,987,000 to 354,696,000, a change of -138,291,000 (-28.1%).
- Net loss of 158,748,000 reduced equity.
- New share issuances of 4,152,000 increased equity.
- Other factors increased equity by 16,305,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-158.75 Million | -44.76% |
| Share Issuances | NT$4.15 Million | +1.17% |
| Other Changes | NT$16.30 Million | +4.6% |
| Total Change | NT$- | -28.05% |
Book Value vs Market Value Analysis
This analysis compares Steminent Biotherapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$-0.23 | NT$88.10 | x |
| 2021-12-31 | NT$6.92 | NT$88.10 | x |
| 2022-12-31 | NT$3.67 | NT$88.10 | x |
| 2023-12-31 | NT$11.07 | NT$88.10 | x |
| 2024-12-31 | NT$6.35 | NT$88.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Steminent Biotherapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -44.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-44.76%) is below the historical average (-34.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -107.27% | 0.51x | 0.00x | NT$-53.91 Million |
| 2021 | -50.85% | -5855.78% | 0.01x | 1.14x | NT$-148.63 Million |
| 2022 | -52.27% | -13439.31% | 0.00x | 1.44x | NT$-101.83 Million |
| 2023 | -26.21% | -13733.16% | 0.00x | 1.20x | NT$-178.53 Million |
| 2024 | -44.76% | 0.00% | 0.00x | 1.23x | NT$-194.22 Million |
Industry Comparison
This section compares Steminent Biotherapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Steminent Biotherapeutics Inc. (7729) | NT$279.82 Million | 0.00% | 0.35x | $23.96K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |